# Biomarkers in Clozapine-responding Schizophrenia

> **NCT05316883** · PHASE4 · RECRUITING · sponsor: **Jimmi Nielsen** · enrollment: 200 (estimated)

## Conditions studied

- Schizophrenia
- Psychosis

## Interventions

- **DRUG:** Clozapine

## Key facts

- **NCT ID:** NCT05316883
- **Lead sponsor:** Jimmi Nielsen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-28
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316883, "Biomarkers in Clozapine-responding Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05316883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*